Emerging as a noteworthy breakthrough in the struggle against obesity, this medication is capturing considerable buzz. It combines properties of two recognized GLP-1 binding agonists, dulaglutide , with an additional glucose-dependent incretin component. Initial patient data have demonstrated sub